drugset / Trial / NCT06043674
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Phase 2
Recruiting
70 enrolled
Christine Ryan
Eli Lilly and Company · collabGenentech, Inc. · collabLoxo Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an antibody-drug conjugate) * Pirtobrutinib (a selective inhibitor of BTK) * Atezolizumab (a humanized immunoglobulin monoclonal antibody) * Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)
Timeline
- Start
- 2024-01-22
- Primary completion
- 2028-01-15
- Completion
- 2033-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Pirtobrutinib | Other / unclassified | 50 mg | Oral |
| Subject | Pirtobrutinib | Other / unclassified | 100 mg | Oral |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |